UBS Group
ELOX

UBS Group’s Eloxx Pharmaceuticals ELOX Stock Holding History

UBS Group’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.84K Buy
+637
New +$8.12K ﹤0.01% 8642

Other funds holding ELOX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
PFO
Pioneer Family Office North Miami Beach, Florida $194M AUM
AS
Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return
OPTFSNA
Old Point Trust & Financial Services N A Newport News, Virginia $329M AUM 22.88% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

UBS Group's ELOX Position: Q2 2026 in Review

UBS Group opened a new position in Eloxx Pharmaceuticals (ELOX) in Q2 2026: 637 shares worth $8.84K. The stake represents ﹤0.01% of the portfolio and ranks #8642 among its holdings.

14 funds tracked by Wall St. Rank hold ELOX as of Q2 2026.

  • UBS Group held 637 shares of Eloxx Pharmaceuticals worth $8.84K as of Q2 2026.
  • Eloxx Pharmaceuticals was a new UBS Group position in Q2 2026.
  • Eloxx Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8642 holding.
  • 14 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.